Home Stock

Stock Research: Lotus Pharmaceutical

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

Lotus Pharmaceutical

TAI:1795 TW0001795003
22
  • Value
    76
  • Growth
    79
  • Safety
    Safety
    4
  • Combined
    43
  • Sentiment
    18
  • 360° View
    360° View
    22
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Lotus Pharmaceutical Co Ltd is a Taiwan-based company focused on manufacturing and selling generic drugs, including solid preparations like tablets and capsules. The company operates in oral anti-cancer drugs, cardiovascular disease drugs, central nervous system drugs, women's health products, osteoporosis drugs, and mental disease drugs, and is also involved in drug research, development, clinical testing, and product licensing. Its main markets are Taiwan, South Korea, the United States, China mainland, Japan, Europe, and Southeast Asia. In the last fiscal year, the company had a market cap of $1963 million, profits of $333 million, and revenue of $567 million.

more

ANALYSIS: With an Obermatt 360° View of 22 (better than 22% compared with alternatives), overall professional sentiment and financial characteristics for the stock Lotus Pharmaceutical are critical, mostly below average. The 360° View is based on consolidating four consolidated indicators, with half of the metrics below and half above average for Lotus Pharmaceutical. The consolidated Value Rank has an attractive rank of 76, which means that the share price of Lotus Pharmaceutical is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 76% of alternative stocks in the same industry. The consolidated Growth Rank has a good rank of 79, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. But the professional market sentiment is below average compared with other stock investment alternatives with a Sentiment Rank of 18. Professional investors are more confident in 82% other stocks. Worryingly, the company has risky financing, with a Safety rank of 4. This means 96% of comparable companies have a safer financing structure than Lotus Pharmaceutical. ...read more

more
Strongest Rank Leverage
Weakest Rank Revenue Growth
Country Taiwan
Industry Pharmaceuticals
Size Medium
Website lotuspharm.com.tw
Index
FTSE Taiwan
Lotus Pharmaceutical stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 10-Aug-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
76 38 38 65
Growth
79 80 87 85
Safety
Safety
4 13 18 18
Sentiment
18 100 90 69
360° View
360° View
22 69 70 79
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
30 93 91 95
Opinions Change
50 50 50 50
Pro Holdings
n/a 100 96 4
Market Pulse
27 100 46 79
Sentiment
18 100 90 69
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
76 38 38 65
Growth
79 80 87 85
Safety Safety
4 13 18 18
Combined
43 38 42 57
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
59 24 24 69
Price vs. Earnings (P/E)
69 74 65 91
Price vs. Book (P/B)
48 22 18 47
Dividend Yield
81 67 64 62
Value
76 38 38 65
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
97 84 82 67
Profit Growth
83 44 69 76
Capital Growth
15 55 51 25
Stock Returns
54 64 71 89
Growth
79 80 87 85
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
1 11 11 8
Refinancing
37 26 29 43
Liquidity
38 22 39 24
Safety Safety
4 13 18 18

Similar Stocks

Discover high‑ranked alternatives to Lotus Pharmaceutical and broaden your portfolio horizons.

CK Asset Holdings

HKG:1113
Country: Hong Kong
Industry: Real Estate Development
Size: X-Large
Full Stock Analysis

Mitsubishi Materials

TYO:5711
Country: Japan
Industry: Diversified Metals & Mining
Size: X-Large
Full Stock Analysis

Phison Electronics

TWO:8299
Country: Taiwan
Industry: Semiconductors
Size: Medium
Full Stock Analysis

Nippon Shinyaku

TYO:4516
Country: Japan
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

Frequently Asked
Questions

This is a mixed bag with good value and high growth balanced by risky financing and negative sentiment. This is a risky stock that requires conviction; you should only consider it if you are willing to conduct further research into the underlying sentiment and financial risks.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews